SCHEMBL6778709

SCHEMBL6778709

NC1=NCCN1c1cccc(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.60
ALDH1A1 P00352 3/20 0.56
HPGD P15428 2/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C9 P11712 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C19 P33261 1/20 0.56
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
GAA P10253 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HSD17B10 Q99714 2/20 0.54
L3MBTL1 Q9Y468 5/20 0.51
MAPT P10636 3/20 0.51
KMO O15229 1/20 0.50
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
POLB P06746 2/20 0.46
USP2 O75604 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27522272 0.91 ALDH1A1 (0.61) SIGMAR1ALDH1A1HPGDCYP2D6CYP2C9
Hydrochloric Acid SCHEMBL6779672 0.90 ALDH1A1 (0.59) SIGMAR1ALDH1A1HPGDCYP2D6CYP2C9
SCHEMBL18762862 0.76 ALDH1A1 (0.47) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL30713414 0.76 ALDH1A1 (0.47) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL1962849 0.73 ALDH1A1 (0.60) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL30444472 0.73 ALDH1A1 (0.60) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL351439 0.72 ALDH1A1 (1.00) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL30281223 0.72 ALDH1A1 (1.00) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL1633474 0.72 KMT2A (0.57) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2
SCHEMBL30422164 0.71 ALDH1A1 (0.61) ALDH1A1HPGDCYP2D6CYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed